Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 6, 2012, Pages 913-921

  Van Besien, Koen ^a   Stock, Wendy ^a   Rich, Elizabeth ^a   Odenike, Olatoyosi ^a   Godley, Lucy A ^a   O'Donnell, Peter H ^a   Kline, Justin ^a   Nguyen, Vu ^a   del Cerro, Paula ^a   Larson, Richard A ^a   Artz, Andrew S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Clofarabine; Conditioning; Phase II; Transplant

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CLOFARABINE; COTRIMOXAZOLE; ECHINOCANDIN; FLUCONAZOLE; GANCICLOVIR; MELPHALAN; QUINOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANAPHYLAXIS; ANXIETY DISORDER; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CANCER TRANSPLANTATION; CARDIOVASCULAR DISEASE; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CONFUSION; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG FATALITY; DRUG MEGADOSE; ENGRAFTMENT; FEMALE; GLOMERULUS FILTRATION RATE; GROUPS BY AGE; HEART ARREST; HEART ATRIUM FLUTTER; HEART FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER FUNCTION; LUNG EMBOLISM; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUTROPHIL; NONHODGKIN LYMPHOMA; OBSTRUCTION; OVERALL SURVIVAL; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PSEUDOTUMOR; SEIZURE; SEPSIS; SHOCK; SIDE EFFECT; SINUSOIDAL OBSTRUCTION; SKIN TOXICITY; SURVIVAL TIME; THROMBOCYTE; TREATMENT RESPONSE; VEIN OCCLUSION;

ACUTE KIDNEY INJURY; ADENINE NUCLEOTIDES; ADULT; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; FEMALE; GLOMERULAR FILTRATION RATE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; RECURRENCE; RISK; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84860841783     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.041     Document Type: Article

References (49)

1. Luger S.M., Ringden O., Zhang M.J., et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2011 Mar 28, [Epub ahead of print].
2. Hari P., Carreras J., Zhang M.J., et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared with myeloablative conditioning. Biol Blood Marrow Transplant 2008, 14:236-245.
3. Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001, 97:631-637.
4. van Besien K., Artz A., Smith S., et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005, 23:5728-5738.
5. Kenkre V.P., Horowitz S., Artz A.S., et al. T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma 2011, 52:214-222.
6. Morris E., Mackinnon S. Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL). Transfus Apher Sci 2005, 32:73-83.
7. Thomson K.J., Morris E.C., Bloor A., et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:426-432.
8. Xie K.C., Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine. Cancer Res 1996, 56:3030-3037.
9. Genini D., Adachi S., Chao Q., et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000, 96:3537-3543.
10. Kantarjian H., Gandhi V., Cortes J., et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003, 102:2379-2386.
11. Jeha S., Razzouk B., Rytting M., et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol 2009, 27:4392-4397.
12. Jeha S., Gandhi V., Chan K.W., et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004, 103:784-789.
13. Nabhan C., Davis N., Bitran J.D., et al. Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Cancer 2011, 117:1490-1497.
14. Faderl S., Ravandi F., Huang X., et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008, 112:1638-1645.
15. Karp J.E., Ricklis R.M., Balakrishnan K., et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007, 110:1762-1769.
16. Locke F.L., Artz A., Rich E., et al. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant 2010, 45:1692-1698.
17. ASBMT RFI Disease classifications. Retrieved September 27, 2011 from . http://asbmt.org/displaycommon.cfm?an=1%26subarticlenbr=35.
18. Simon R., Freidlin B., Rubinstein L., et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997, 89:1138-1147.
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
20. Pocock S. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977, 64:191-199.
21. Kline J., Pollyea D.A., Stock W., et al. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant 2006, 37:307-310.
22. van Besien K., Dew A., Lin S., et al. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma 2009, 50:1809-1817.
23. Common terminology criteria for adverse events (CTCAE) and common toxicity criteria (CTC). Retrieved on September 28, 2011 from . http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
24. Przepiorka D., Weisdorf D., Martin P., et al. Consensus conference on GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
25. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
26. CIBMTR data management manual. Retrieved on September 28, 2011 from . http://www.cibmtr.org/DataManagement/TrainingReference/Manuals/DataManagement/pages/index.aspx.
27. Klein J.P., Rizzo J.D., Zhang M.J., Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant 2001, 28:909-915.
28. Cox D.R. Regression models and life tables (with discussions). J R Statist Soc B 1972, 34:187-220.
29. Scrucca L., Santucci A., Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 2010, 45:1388-1395.
30. Cirillo M., Lombardi C., Luciano M.G., et al. Estimation of GFR: a comparison of new and established equations. Am J Kidney Dis 2010, 56:802-804.
31. Kantarjian H.M., Gandhi V., Kozuch P., et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003, 21:1167-1173.
32. Farag S.S., Wood L.L., Schwartz J.E., et al. Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia. Leukemia 2011, 25:599-605.
33. Mineishi S., Magenau J., Tobai H., et al. Allogeneic hematopoietic stem cell transplantation with clofarabine/busulfan × 4 conditioning exhibits significant anti-tumor activity in non-remission hematologic malignancies, especially in AML. Blood 2010, 116:a35.
34. Andersson B.S., Valdez B.C., de Lima M., et al. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 2011, 17:893-900.
35. Ricci A.M., Geyer M.B., Harrison L.A., et al. Preliminary results of phase I/II study of clofarabine incombination with cytarabine and total body irradiation followed by allogeneic stem cell transplantation in children, adolescents and young adults with poor-risk acute leukemia. Biol Blood Marrow Transplant 2011, 17:S186.
36. Teltschik H., Mueller I., Pfeiffer M., et al. Clofarabine versus fludarabine for haploidentical stem cell transplantation in paediatric patients with refractory leukaemias. Bone Marrow Transplant 2009, 43:S224.
37. Agura E., Berryman R.B., Luis P., et al. Preliminary results of a phase II trial of clofarabine with parenteral busulfan followed by allogeneic transplantation for the treatment of hematologic malignancies. Biol Blood Marrow Transplant 2011, 17:S298.
38. Kirschbaum M.H., Stein A.S., Popplewell L., et al. A phase I study in adults of clofarabine combined with high-dose melphalan as reduced intensity conditioning for allogeneic transplantation. Biol Blood Marrow Transplant 2011 Jul 27, [Epub ahead of print].
39. van Besien K., Kunavakkam R., Rondon G., et al. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 2009, 15:610-617.
40. Socie G., Schmoor C., Bethge W.A., et al. Chronic graft-versus-host disease: long-term results from a randomized trial on GvHD prophylaxis with or without anti-T-cell globulin ATG-fresenius. Blood 2011, 117:6375-6382.
41. O'Donnell P.H., Artz A.S., Undevia S.D., et al. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma 2010, 51:2154-2156.
42. van Besien K., Schouten V., Parsad S., et al. Allogeneic stem cell transplantation in renal failure. engraftment and prolonged survival, but high incidence of neurologic toxicity. Leuk Lymphoma 2011, [Epub ahead of print].
43. Faderl S., Verstovsek S., Cortes J., et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006, 108:45-51.
44. Jeha S., Gaynon P.S., Razzouk B.I., et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006, 24:1917-1923.
45. Morandi P., Ruffini P.A., Benvenuto G.M., Raimondi R., Fosser V. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant 2005, 35:323-334.
46. van Besien K., Devine S., Wickrema A., et al. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant 2003, 32:471-476.
47. Lenihan D.J., Alencar A.J., Yang D., et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 2004, 104:655-658.
48. Beitinjaneh A., McKinney A.M., Cao Q., Weisdorf D.J. Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:300-308.
49. Martin M.G., Uy G.L., Procknow E., et al. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. Bone Marrow Transplant 2009, 44:13-17.